Literature DB >> 15231843

Crystal structure of Mycobacterium tuberculosis catalase-peroxidase.

Thomas Bertrand1, Nigel A J Eady, Jamie N Jones, Judit M Nagy, Brigitte Jamart-Grégoire, Emma Lloyd Raven, Katherine A Brown.   

Abstract

The Mycobacterium tuberculosis catalase-peroxidase is a multifunctional heme-dependent enzyme that activates the core anti-tuberculosis drug isoniazid. Numerous studies have been undertaken to elucidate the enzyme-dependent mechanism of isoniazid activation, and it is well documented that mutations that reduce activity or inactivate the catalase-peroxidase lead to increased levels of isoniazid resistance in M. tuberculosis. Interpretation of the catalytic activities and the effects of mutations upon the action of the enzyme to date have been limited due to the lack of a three-dimensional structure for this enzyme. In order to provide a more accurate model of the three-dimensional structure of the M. tuberculosis catalase-peroxidase, we have crystallized the enzyme and now report its crystal structure refined to 2.4-A resolution. The structure reveals new information about dimer assembly and provides information about the location of residues that may play a role in catalysis including candidates for protein-based radical formation. Modeling and computational studies suggest that the binding site for isoniazid is located near the delta-meso heme edge rather than in a surface loop structure as currently proposed. The availability of a crystal structure for the M. tuberculosis catalase-peroxidase also permits structural and functional effects of mutations implicated in causing elevated levels of isoniazid resistance in clinical isolates to be interpreted with improved confidence.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15231843     DOI: 10.1074/jbc.M402382200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  Differential Sensitivity of Mycobacteria to Isoniazid Is Related to Differences in KatG-Mediated Enzymatic Activation of the Drug.

Authors:  Tali H Reingewertz; Tom Meyer; Fiona McIntosh; Jaryd Sullivan; Michal Meir; Yung-Fu Chang; Marcel A Behr; Daniel Barkan
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

2.  Mutations prevalent among rifampin- and isoniazid-resistant Mycobacterium tuberculosis isolates from a hospital in Vietnam.

Authors:  M Caws; Phan Minh Duy; Dau Quang Tho; Nguyen Thi Ngoc Lan; Dai Viet Hoa; Jeremy Farrar
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

3.  Radical sites in Mycobacterium tuberculosis KatG identified using electron paramagnetic resonance spectroscopy, the three-dimensional crystal structure, and electron transfer couplings.

Authors:  Kalina Ranguelova; Stefania Girotto; Gary J Gerfen; Shengwei Yu; Javier Suarez; Leonid Metlitsky; Richard S Magliozzo
Journal:  J Biol Chem       Date:  2007-01-04       Impact factor: 5.157

4.  Role of the oxyferrous heme intermediate and distal side adduct radical in the catalase activity of Mycobacterium tuberculosis KatG revealed by the W107F mutant.

Authors:  Xiangbo Zhao; Shengwei Yu; Kalina Ranguelova; Javier Suarez; Leonid Metlitsky; Johannes P M Schelvis; Richard S Magliozzo
Journal:  J Biol Chem       Date:  2009-01-12       Impact factor: 5.157

5.  Mutations in catalase-peroxidase KatG from isoniazid resistant Mycobacterium tuberculosis clinical isolates: insights from molecular dynamics simulations.

Authors:  Arethusa Lobo Pimentel; Regiane Bertin de Lima Scodro; Katiany Rizzieri Caleffi-Ferracioli; Vera Lúcia Dias Siqueira; Paula Aline Zanetti Campanerut-Sá; Luciana Dias Ghiraldi Lopes; Aryadne Larissa de Almeida; Rosilene Fressatti Cardoso; Flavio Augusto Vicente Seixas
Journal:  J Mol Model       Date:  2017-03-16       Impact factor: 1.810

6.  Withdrawn

Authors: 
Journal:  Infect Disord Drug Targets       Date:  2012-11-16

7.  Binding of the anti-tubercular drug isoniazid to the arylamine N-acetyltransferase protein from Mycobacterium smegmatis.

Authors:  James Sandy; Simon Holton; Elizabeth Fullam; Edith Sim; Martin Noble
Journal:  Protein Sci       Date:  2005-03       Impact factor: 6.725

Review 8.  Tuberculosis: drug resistance, fitness, and strategies for global control.

Authors:  Erik C Böttger; Burkhard Springer
Journal:  Eur J Pediatr       Date:  2007-11-07       Impact factor: 3.183

9.  Mode of binding of the tuberculosis prodrug isoniazid to heme peroxidases: binding studies and crystal structure of bovine lactoperoxidase with isoniazid at 2.7 A resolution.

Authors:  Amit K Singh; Ramasamy P Kumar; Nisha Pandey; Nagendra Singh; Mau Sinha; Asha Bhushan; Punit Kaur; Sujata Sharma; Tej P Singh
Journal:  J Biol Chem       Date:  2009-11-11       Impact factor: 5.157

10.  Isoniazid-resistance conferring mutations in Mycobacterium tuberculosis KatG: catalase, peroxidase, and INH-NADH adduct formation activities.

Authors:  Christine E Cade; Adrienne C Dlouhy; Katalin F Medzihradszky; Saida Patricia Salas-Castillo; Reza A Ghiladi
Journal:  Protein Sci       Date:  2010-03       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.